FDA Aims To Regulate Clinical Trial Third-Party Investigators
This article was originally published in The Pink Sheet Daily
The agency is working on a proposed rule that would require companies to report data falsification by sub-investigators, according to deputy commissioner Woodcock.
You may also be interested in...
To avoid public pushback, the Critical Path initiative should focus on science, not regulatory overhauls, Woodcock tells DIA.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.